163 related articles for article (PubMed ID: 1079053)
1. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs.
Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N
J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053
[TBL] [Abstract][Full Text] [Related]
2. alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase.
Palfreyman MG; Danzin C; Bey P; Jung MJ; Ribereau-Gayon G; Aubry M; Vevert JP; Sjoerdsma A
J Neurochem; 1978 Oct; 31(4):927-32. PubMed ID: 308998
[No Abstract] [Full Text] [Related]
3. Interaction of DOPA decarboxylase inhibitors with the effect of alpha-methyldopa on blood pressure and tissue monoamines in rats.
Henning M
Acta Pharmacol Toxicol (Copenh); 1969; 27(2):135-48. PubMed ID: 5819569
[No Abstract] [Full Text] [Related]
4. On the mechanism of L-dopa-induced postural hypotension in the cat.
Dhasmana KM; Spilker BA
Br J Pharmacol; 1973 Mar; 47(3):437-51. PubMed ID: 4147189
[TBL] [Abstract][Full Text] [Related]
5. Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor.
Ribéreau-Gayon G; Palfreyman MG; Zraïka M; Wagner J; Jung MJ
Biochem Pharmacol; 1980 Sep; 29(18):2465-9. PubMed ID: 7426053
[No Abstract] [Full Text] [Related]
6. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
Huebert ND; Palfreyman MG; Haegele KD
Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
[TBL] [Abstract][Full Text] [Related]
7. Comparison of centrally mediated hypotensive action of methyldopa and DOPA in cats.
Torchiana ML; Lotti VJ; Clark CM; Stone CA
Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):103-13. PubMed ID: 4148405
[No Abstract] [Full Text] [Related]
8. Block of cerebral actions of L-dopa with methyl receptor substances.
Cotzias GC; Tang L; Ginos JZ; Nicholson AR; Papavasiliou PS
Nature; 1971 Jun; 231(5304):533-5. PubMed ID: 4934569
[No Abstract] [Full Text] [Related]
9. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs.
Furuta Y; Hashimoto K; Iwatsuki K; Takeuchi O
Br J Pharmacol; 1973 Jan; 47(1):77-84. PubMed ID: 4717022
[TBL] [Abstract][Full Text] [Related]
10. gamma-Glutamyl dopa: a kidney-specific dopamine precursor.
Wilk S; Mizoguchi H; Orlowski M
J Pharmacol Exp Ther; 1978 Jul; 206(1):227-32. PubMed ID: 660553
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
Cohen Y; Wepierre J; Jacquot C; Rapin J
Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):348-60. PubMed ID: 4827419
[No Abstract] [Full Text] [Related]
12. The effect of various agents on the pressor response to dopa in the anesthetized dog.
Pruss TP; McGill JS
Eur J Pharmacol; 1969 Oct; 8(1):14-8. PubMed ID: 4391043
[No Abstract] [Full Text] [Related]
13. On the localization of the hypotensive effect of L-dopa.
Henning M; Rubenson A; Trolin G
J Pharm Pharmacol; 1972 Jun; 24(6):447-51. PubMed ID: 4403826
[No Abstract] [Full Text] [Related]
14. Synthesis of substituted DL-3(5-benzazolyl)alanines as dopa and alpha-methyldopa analogs and their effects on dopamine beta-hydroxylase, tyrosinase and diphenoloxidase.
Loriga M; Paglietti G; Sparatore F; Pinna G; Sisini A
Farmaco; 1992 Apr; 47(4):439-48. PubMed ID: 1388592
[TBL] [Abstract][Full Text] [Related]
15. (S)-norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS).
Porter CC; Torchiana ML; Stone CA
Life Sci I; 1972 Aug; 11(16):787-95. PubMed ID: 4540250
[No Abstract] [Full Text] [Related]
16. Inactivation of 3-(3,4-dihydroxyphenyl)alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine.
Maycock AL; Aster SD; Patchett AA
Biochemistry; 1980 Feb; 19(4):709-18. PubMed ID: 7356954
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects of alpha-acetylenic DOPA and alpha-vinyl DOPA on aromatic L-amino acid decarboxylase.
Ribéreau-Gayon G; Danzin C; Palfreyman MG; Aubry M; Wagner J; Metcalf BW; Jung MJ
Biochem Pharmacol; 1979 Apr; 28(8):1331-5. PubMed ID: 312645
[No Abstract] [Full Text] [Related]
18. On the role of alpha-methyldopamine in the antihypertensive effect of alpha-methyldopa.
Waldmeier P; Hedwal PR; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1975; 289(3):303-14. PubMed ID: 169487
[TBL] [Abstract][Full Text] [Related]
19. Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa.
Bey P; Jung MJ; Koch-Weser J; Palfreyman MG; Sjoerdsma A; Wagner J; Zraïka M
Br J Pharmacol; 1980 Dec; 70(4):571-6. PubMed ID: 7470730
[TBL] [Abstract][Full Text] [Related]
20. Further studies on the mechanism of the central hypotensive effect of L-dopa, DL-m-tyrosine and L-alpha-methyldopa.
Rubenson A
J Pharm Pharmacol; 1971 Mar; 23(3):228-30. PubMed ID: 4396899
[No Abstract] [Full Text] [Related]
[Next] [New Search]
